Sorafenib in Treating Patients With Relapsed Chronic Lymphocytic Leukemia
Status:
Terminated
Trial end date:
2011-05-01
Target enrollment:
Participant gender:
Summary
Sorafenib may stop the growth of cancer cells by blocking some of the enzymes needed for cell
growth and by blocking blood flow to the cancer. This phase II trial is studying how well
sorafenib works in treating patients with relapsed chronic lymphocytic leukemia.